Yee Hoong Ong currently serves as Senior Manager at the Advanced Cell Therapy and Research Institute in Singapore, starting in September 2023, where responsibilities include the tech transfer of cell therapy processes into GMP-compliant production. Previously, Yee Hoong Ong held multiple roles at Tessa Therapeutics Ltd from July 2015 to June 2023, including Senior Scientist focused on CAR-T cell manufacturing improvements and assay development, and Manufacturing Manager in both continuous improvement and operations, overseeing key projects and the manufacturing processes for Phase III clinical studies. Prior experiences include serving as Product Sales Executive at Chemoscience Sdn Bhd and as a Chemist at Lion Petroleum Products Sdn Bhd. Academic qualifications encompass a PhD in Cell/Cellular and Molecular Biology from Taylor's University, a Masters of Science Preliminary in Biotechnology from Monash University Malaysia, and a Bachelor of Science in Biotechnology from Monash University Malaysia.
This person is not in any teams
Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)
Cell, tissue and gene therapy (CTGT) involves the introduction of whole genetically- or non-genetically modified cells into a patient to carry out an immunotherapeutic or regenerative function to treat diseases and/or damaged organs. CTGT as witnessed by the regulatory approval of several life-saving products will be a rapidly evolving and developing field in the medical and pharmaceutical ecosystem for the years to come. To better support the growing demand for CTGT in Singapore, a new national-level organization, Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), was established on the 20th of April 2020. Formally known as National Cell Therapy Centre (working name), ACTRIS is a business unit of Consortium for Clinical Research and Innovation, Singapore (CRIS), which is a wholly owned subsidiary of Ministry of Health Holdings (MOHH). ACTRIS’s vision is to be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine encompassing investigational and approved CTGTs. The core capabilities of ACTRIS will include process development and validation; clinical manufacturing; product characterisation along with regulatory and clinical facilitation. ACTRIS will also provide state-of-the-art manufacturing facility, equipment, regulatory-compliant quality management system and skilled manpower to carry out the end-to-end manufacturing services for CTGTs.